Please assess the completion status of the following clinical trial:

Trial Title: Alpha Lipoic Acid for Treatment of Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic patients (according to American Diabetes Association (ADA) criteria)~* Symptomatic diabetic polyneuropathy~* Total Symptom Score (TSS) \>7 points,~* HbA1c\<10%,~* Serum creatinine \<2 mg/dl.~Exclusion Criteria:~* Active cardiovascular disease~* Malignancy~* Any other conditions causing neuropathic pain~* Use of analgesic, antidepressant, or antiepileptic drugs, or any other medication aimed to relief neuropathic pain.~* Child-bearing female patients not using any effective birth control method and under surveillance of a board-certified gynecologist

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alpha lipoic acid treatment (Type: ACTIVE_COMPARATOR): After a decrease in the total symptoms score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
- alpha lipoic acid withdrawal (Type: NO_INTERVENTION): After a decrease in the total symptoms Score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).